KYMR

+ Watchlist + Portfolio

Kymera Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $110.12
52-Week Range: $55.26 – $130.05
Market Cap: $8.93B
P/E (TTM): —
EPS (TTM): -3.25
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 5.89
PEG Ratio: —
Return on Equity: -24.15%
Return on Assets: -15.59%
Gross Margin: -257.69%
Operating Margin: -116.32%
Profit Margin: -285.33%
Current Ratio: 10.34
Debt/Equity: 0.05
Total Debt: $78.56M
Free Cash Flow: $-144.07M
Revenue Growth: 466.40%
Earnings Growth: —
Enterprise Value: $8.32B

KYMR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$46.83M	$78.59M	$47.07M	$39.21M
Research & Development	$164.25M	$189.08M	$240.25M	$316.57M
Selling, General & Admin	$43.83M	$55.04M	$63.53M	$68.19M
Operating Expenses	$208.08M	$244.12M	$303.78M	$384.75M
Operating Income	-$161.26M	-$165.53M	-$256.71M	-$345.54M
EBITDA	-$151.66M	-$143.20M	-$216.24M	-$302.67M
Pretax Income	-$154.81M	-$146.96M	-$223.86M	-$311.35M
Net Income	-$154.81M	-$146.96M	-$223.86M	-$311.35M
Diluted EPS	-2.87	-2.52	-2.98	-3.69
Diluted Shares	53.93M	58.37M	75.04M	84.49M

KYMR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$68.39M	$109.97M	$120.26M	$357.01M
Receivables	$2.54M	$18.76M	$947.00K	—
Current Assets	$419.42M	$405.32M	$510.27M	$871.21M
Total Assets	$603.13M	$575.76M	$978.03M	$1.74B
Current Liabilities	$71.34M	$85.69M	$67.77M	$83.21M
Total Debt	$17.34M	$84.67M	$87.76M	$82.25M
Total Liabilities	$112.98M	$180.79M	$142.42M	$163.15M
Retained Earnings	-$383.79M	-$530.75M	-$754.61M	-$1.07B
Shareholders' Equity	$490.15M	$394.97M	$835.62M	$1.58B
Working Capital	$348.07M	$319.63M	$442.50M	$788.00M

KYMR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$153.09M	-$102.83M	-$194.50M	-$232.89M
Capital Expenditure	-$2.84M	-$34.48M	-$12.84M	-$1.45M
Free Cash Flow	-$155.92M	-$137.31M	-$207.34M	-$234.34M
Depreciation & Amortisation	$2.98M	$3.56M	$7.37M	$8.31M
Stock-Based Compensation	$35.48M	$43.12M	$55.01M	$59.90M
Investing Cash Flow	$20.52M	$139.89M	-$404.08M	-$521.06M
Financing Cash Flow	$153.00M	$4.19M	$608.85M	$990.71M
Net Change in Cash	$20.43M	$41.25M	$10.27M	$236.76M

KYMR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$22.10M	$11.48M	$2.76M	$2.87M	$34.37M	$65.00M
Research & Development	$80.25M	$78.39M	$74.09M	$83.83M	$98.16M	$119.48M
Selling, General & Admin	$16.27M	$17.64M	$17.34M	$16.93M	$20.36M	$21.13M
Operating Expenses	$96.53M	$96.03M	$91.43M	$100.77M	$118.52M	$140.61M
Operating Income	-$74.43M	-$84.56M	-$88.67M	-$97.90M	-$84.15M	-$75.61M
EBITDA	-$63.46M	-$74.42M	-$79.93M	-$84.86M	-$67.15M	-$59.10M
Pretax Income	-$65.58M	-$76.61M	-$82.17M	-$86.98M	-$69.23M	-$61.21M
Net Income	-$65.58M	-$76.61M	-$82.17M	-$86.98M	-$69.23M	-$61.21M
Diluted EPS	-0.82	-0.95	-0.94	-0.97	-0.71	-0.62
Diluted Shares	80.15M	80.45M	87.30M	89.91M	97.53M	98.18M

KYMR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$89.97M	$335.82M	$112.95M	$357.01M	$144.09M	$124.48M
Receivables	$20.00M	$40.00M	$0.00	—	—	$20.00M
Current Assets	$500.95M	$728.33M	$528.30M	$871.21M	$677.43M	$737.26M
Total Assets	$918.31M	$1.13B	$1.10B	$1.74B	$1.67B	$1.65B
Current Liabilities	$58.99M	$87.54M	$71.58M	$83.21M	$62.64M	$71.33M
Total Debt	$86.33M	$85.71M	$84.00M	$82.25M	$80.47M	$78.56M
Total Liabilities	$132.08M	$159.59M	$155.79M	$163.15M	$129.38M	$136.19M
Retained Earnings	-$820.19M	-$896.80M	-$978.98M	-$1.07B	-$1.14B	-$1.20B
Shareholders' Equity	$786.23M	$971.48M	$946.26M	$1.58B	$1.54B	$1.51B
Working Capital	$441.96M	$640.79M	$456.72M	$788.00M	$614.79M	$665.94M

KYMR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$79.15M	-$59.88M	-$27.11M	-$66.75M	-$88.84M	-$54.06M
Capital Expenditure	-$467.00K	-$695.00K	-$181.00K	-$106.00K	-$434.00K	-$473.00K
Free Cash Flow	-$79.62M	-$60.58M	-$27.29M	-$66.85M	-$89.27M	-$54.54M
Depreciation & Amortisation	$2.05M	$2.08M	$2.15M	$2.03M	$2.02M	$2.03M
Stock-Based Compensation	$14.23M	$15.42M	$15.80M	$14.45M	$16.01M	$18.94M
Investing Cash Flow	$48.62M	$60.02M	-$235.30M	-$394.40M	-$142.84M	$20.05M
Financing Cash Flow	$258.00K	$245.73M	$39.51M	$705.22M	$18.77M	$14.42M
Net Change in Cash	-$30.28M	$245.86M	-$222.90M	$244.07M	-$212.91M	-$19.60M

Market Snapshot

About

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing protein degradation therapies. The company's proprietary Pegasus platform enables the discovery of small molecule protein degraders that target disease-causing proteins for destruction. Kymera's pipeline includes investigational treatments for immunological diseases, oncology, and other therapeutic areas, utilizing targeted protein degradation as a novel mechanism of action.